Novo Nordisk on Track for Record High Close — Data Talk
Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $143.47, up $0.59 or 0.41%
--Would be new all-time high (Based on available data back to April 30, 1981)
--Currently up eight consecutive days; up 8.13% over this period
--Longest winning streak since April 3, 2023, when it rose for eight straight trading days
--Best eight day stretch since the eight days ending May 15, 2024, when it rose 9.44%
--Up 6.05% month-to-date
--Up 38.69% year-to-date
--Up 80.75% from 52 weeks ago (June 12, 2023), when it closed at $79.38
--Would be a new 52-week closing high
--Up 88.47% from its 52-week closing low of $76.13 on July 11, 2023
--Traded as high as $143.62
--Up 0.52% at today's intraday high
All data as of 1:53:46 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
June 10, 2024 14:10 ET (18:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations